Inflammasome activation in end-stage heart failure-associated atrial fibrillation.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
08 2022
Historique:
revised: 23 04 2022
received: 30 11 2021
accepted: 04 05 2022
pubmed: 20 5 2022
medline: 20 7 2022
entrez: 19 5 2022
Statut: ppublish

Résumé

Inflammatory pathways are increasingly recognized as an important factor in the pathophysiology of both heart failure (HF) and atrial fibrillation (AF). However, there is no data about inflammation-related histological and molecular alterations in HF-associated AF. The objective of our study was to investigate inflammatory pathways and fibrosis in end-stage HF-associated AF. Left atrial samples of 24 male patients with end stage ischemic HF undergoing heart transplantation were analysed. Twelve patients suffered from sustained AF while the others had no documented AF. The expression of inflammasome sensors and their downstream signalling were investigated by Western blot. No differences were observed in the expression of inflammasome sensors between the two groups, while cleaved caspase-1 increased tendentiously in the AF group (P = 0.051). Cleaved caspase-1 also showed significant correlation with the expression of interleukin-1β and its cleaved form in the total population and in the AF group (P < 0.05). The presence of myocardial and epicardial macrophages were assessed by ionized calcium-binding adaptor molecule 1 (Iba1) immunostaining. Number of macrophages showed a tendency towards elevation in the left atrial myocardium and epicardium of AF compared with SR group. The amount of total and interstitial fibrosis was determined on Masson's trichrome-stained sections. Histological assessment revealed no difference between AF and SR groups in the amount of either total or interstitial fibrosis. This is the first study on inflammation-related differences between HF with SR or AF showing elevated inflammasome activity and enhanced macrophage infiltration in left atrial samples of patients with AF.

Identifiants

pubmed: 35585786
doi: 10.1002/ehf2.13972
pmc: PMC9288748
doi:

Substances chimiques

Inflammasomes 0
Caspases EC 3.4.22.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2747-2752

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Heart Rhythm. 2010 Apr;7(4):438-44
pubmed: 20153266
Kardiol Pol. 2008 Jul;66(7):729-36; discussion 737-9
pubmed: 18690564
PLoS One. 2014 Jun 12;9(6):e99495
pubmed: 24923671
Circ Res. 2020 Sep 25;127(8):1036-1055
pubmed: 32762493
Cardiovasc Res. 2021 Nov 22;117(13):2639-2651
pubmed: 34117866
J Am Heart Assoc. 2021 Apr 20;10(8):e019168
pubmed: 33843247
ESC Heart Fail. 2022 Aug;9(4):2747-2752
pubmed: 35585786
Circulation. 2018 Nov 13;138(20):2227-2242
pubmed: 29802206

Auteurs

Szilvia Kugler (S)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Zsófia Onódi (Z)

Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
HCEMM-SU Cardiometabolic Immunology Research Group, Budapest, Hungary.
MTA-SE "Momentum" Cardio-Oncology and Cardioimmunology Research Group, Budapest, Hungary.

Mihály Ruppert (M)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Alex Ali Sayour (AA)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Attila Oláh (A)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Kálmán Benke (K)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Péter Ferdinandy (P)

Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Pharmahungary Group, Szeged, Hungary.

Béla Merkely (B)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Tamás Radovits (T)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Zoltán V Varga (ZV)

Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
HCEMM-SU Cardiometabolic Immunology Research Group, Budapest, Hungary.
MTA-SE "Momentum" Cardio-Oncology and Cardioimmunology Research Group, Budapest, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH